Why did GAAP EPS guidance decline while Adjusted EPS guidance increased?

The filing says the GAAP EPS guidance of approximately $13.77 excludes non-GAAP items. The largest adjustments in the FY 2025 bridge are put/call valuation adjustments of $3.01 per share tied to non-consolidating minority interest investments, which relate to the company's primary care strategic partnership and are fair value measurements. Adjusted guidance of approximately $17.00 excludes these items, along with amortization, value creation initiatives, and impairment charges.

What drove the year-over-year change in Insurance segment results?

The filing says Insurance segment revenues rose on higher per member Medicare and state-based contract premiums, with the Medicare increase largely driven by an increased direct subsidy due to the Inflation Reduction Act, plus membership growth in state-based contracts and stand-alone PDP. Partly offsetting this was the individual Medicare Advantage membership decline, including plan and county exits. The quarterly benefit ratio increased, reflecting a shift in line of business mix and incremental investments in member outcomes.

What did management say about membership and the Medicare Advantage margin outlook?

The prepared remarks state that year-to-date individual Medicare Advantage membership declined by approximately 432,500, ahead of expectations due to better-than-anticipated sales. Plan and county exits affected approximately 560,000 members, and about 43 percent of those members were recaptured into other Humana MA plans as of the quarter. Management said it is committed to achieving an individual MA pretax margin of at least 3 percent over time.

What is the outlook for the third quarter and capital deployment?

The prepared remarks expect third-quarter earnings to be approximately 15% to 20% of expected FY 2025 Adjusted earnings, with the Insurance segment benefit ratio expected to be just above 91 percent. The company said its 2025 outlook contemplates minimal share repurchase activity to offset dilution from stock-based compensation, citing the expected Stars headwind in 2026. It reported no amount drawn on its 5-year $5.0 billion revolver and no outstanding commercial paper as of June 30, 2025.

HUM 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Humana Inc. (NYSE: HUM) furnished this Form 8-K under Items 2.02 and 7.01 to report financial results for the quarter ended June 30, 2025 (2Q25).

The company reported GAAP diluted EPS of $4.51^a for 2Q25 versus $5.62 in 2Q24, and Adjusted EPS of $6.27 versus $6.96. Year-to-date GAAP diluted EPS was $14.81 and Adjusted EPS was $17.85. The Insurance segment benefit ratio was 89.9 percent for 2Q25, in line with the company's previously disclosed expectation of approximately 90 percent.

Consolidated revenues were $32,388 million^b for 2Q25 compared with $29,540 million a year earlier. Humana raised its full-year 2025 Adjusted EPS guidance to approximately $17.00 from approximately $16.25, while lowering its GAAP EPS guidance to approximately $13.77 from approximately $14.68. The company raised its consolidated revenue guidance to at least $128 billion from a range of $126 billion to $128 billion.

It affirmed the Insurance segment benefit ratio guidance of 90.1 to 90.5 percent and revised its expected individual Medicare Advantage membership decline to up to 500,000 members from approximately 550,000. Management's prepared remarks state the updated Adjusted EPS outlook includes approximately $100 million^c of incremental investments in member and patient outcomes and operational excellence. The filing also reports that CenterWell Primary Care now anticipates 2025 net patient growth of 50,000 to 70,000, up from 30,000 to 50,000.

Days in claims payable fell to 36.5 days from 41.6 days a year earlier, and debt-to-total capitalization was 40.7 percent at June 30, 2025. The filing attaches a press release, a detailed earnings release with statistical schedules, and prepared management remarks.

02—Key points

Key Highlights

2Q25 GAAP diluted EPS of $4.51 versus $5.62 in 2Q24; Adjusted EPS of $6.27 versus $6.96
YTD 2025 GAAP diluted EPS of $14.81 and Adjusted EPS of $17.85, versus $11.74 and $14.19 a year earlier
FY 2025 Adjusted EPS guidance raised to approximately $17.00 from approximately $16.25; GAAP EPS guidance lowered to approximately $13.77 from approximately $14.68
FY 2025 consolidated revenue guidance raised to at least $128 billion from $126 billion to $128 billion
Individual Medicare Advantage membership decline now expected to be up to 500,000, versus approximately 550,000 previously
2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the approximately 90 percent expectation; FY 2025 range of 90.1 to 90.5 percent affirmed
Debt-to-total capitalization fell to 40.7 percent at June 30, 2025 from 43.6 percent a year earlier; days in claims payable were 36.5 versus 41.6

03—Questions

Frequently Asked Questions

Why did GAAP EPS guidance decline while Adjusted EPS guidance increased?
The filing says the GAAP EPS guidance of approximately $13.77 excludes non-GAAP items. The largest adjustments in the FY 2025 bridge are put/call valuation adjustments of $3.01 per share tied to non-consolidating minority interest investments, which relate to the company's primary care strategic partnership and are fair value measurements. Adjusted guidance of approximately $17.00 excludes these items, along with amortization, value creation initiatives, and impairment charges.
What drove the year-over-year change in Insurance segment results?
The filing says Insurance segment revenues rose on higher per member Medicare and state-based contract premiums, with the Medicare increase largely driven by an increased direct subsidy due to the Inflation Reduction Act, plus membership growth in state-based contracts and stand-alone PDP. Partly offsetting this was the individual Medicare Advantage membership decline, including plan and county exits. The quarterly benefit ratio increased, reflecting a shift in line of business mix and incremental investments in member outcomes.
What did management say about membership and the Medicare Advantage margin outlook?
The prepared remarks state that year-to-date individual Medicare Advantage membership declined by approximately 432,500, ahead of expectations due to better-than-anticipated sales. Plan and county exits affected approximately 560,000 members, and about 43 percent of those members were recaptured into other Humana MA plans as of the quarter. Management said it is committed to achieving an individual MA pretax margin of at least 3 percent over time.
What is the outlook for the third quarter and capital deployment?
The prepared remarks expect third-quarter earnings to be approximately 15% to 20% of expected FY 2025 Adjusted earnings, with the Insurance segment benefit ratio expected to be just above 91 percent. The company said its 2025 outlook contemplates minimal share repurchase activity to offset dilution from stock-based compensation, citing the expected Stars headwind in 2026. It reported no amount drawn on its 5-year $5.0 billion revolver and no outstanding commercial paper as of June 30, 2025.

04—Continue

← View all 8-K filings